Veterinary Product Information
Veda-K1 Capsules
This page contains information on Veda-K1 Capsules for veterinary use.The information provided typically includes the following:
- Veda-K1 Capsules Indications
- Warnings and cautions for Veda-K1 Capsules
- Direction and dosage information for Veda-K1 Capsules
Veda-k1 Capsules
This treatment applies to the following species:Active Ingredient(s)
Each capsule contains:|
Phytonadione |
25 mg |
Veda-K1 Capsules Indications
Vitamin K1 capsules are indicated in dogs and cats to counter hypoprothrombinemia induced by ingestion of coumarin-based compounds, common ingredients in commercial rodenticides, and other drug induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g. salicylates.Veda-K1 Capsules Dosage And Administration
Dogs and Cats: Acute hypoprothrombinemia (with hemorrhage) - Administer orally at the rate of 2.5-5 mg/kg of body weight (1 capsule per each 11 pounds of body weight for higher dosage) once a day as conditions require for up to three (3) weeks. The frequency and amount of oral administration should be guided by regular determination of prothrombin time.Note: Regular determinations of prothrombin time response should be performed to guide in the initial and subsequent administration of Vitamin K1 oral capsules. The dosage should be adjusted accordingly.
Precaution(s)
Protect from light at all times.Veda-K1 Capsules Caution(s)
Keep out of the reach of children.Temporarily resistance to prothrombin-depressing anticoagulants may result, especially when larger doses of phytonadione are used.
It is recommended that Vitamin K1 capsules be used in follow-up therapy only after an administration of Vitamin K1 injection and hospitalization is no longer required. An immediate coagulant effect should not be expected after the administration of phytonadione when administered orally. Phytonadione will not counteract the anticoagulant action of heparin.
Repeated large doses of Vitamin K1 are not warranted in hepatic disease if the response to the initial therapy is unsatisfactory. Failure to respond to Vitamin K1 may indicate that the condition being treated is inherently unresponsive to Vitamin K1.
Presentation
50 capsule, 25 mg containers.Nac No.
109420605503 CORPORATE DR., ST. JOSEPH, MO, 64507
| Telephone: | 816-238-8840 | |
| Toll-Free: | 888-708-3326 (888-70VEDCO) | |
| Fax: | 816-238-1837 | |
| Website: | www.vedco.com/dvmonly/ |
![]() |
Every effort has been made to ensure the accuracy of the Veda-K1 Capsules information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Veda-K1 Capsules product label or package insert. |
![]() |
Printable Version | ![]() |
Email Page |








